This treatment required escape of the nano drug from the vasculature and subsequent permeation of the tumor matrix and tumor cell membranes achieved by the combined sequential action of antibodies against TfR and anti-HER2 (Herceptin). This evidence concerns the gene ERBB2 and neoplasm.